Biogen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biogen sits in the top decile of US sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count).
Biogen: 334 sponsored US clinical trials, 21 recruiting.
Biogen sponsors 334 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 237 completed. 84 of these trials are in Phase 3-4 (later-stage) and 198 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 13 trials.
Top-decile sponsor footprint
Biogen ranks in the top decile of sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
237 of 302 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
334 total, page 3 of 7
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
NCT03283371
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
NCT03088956
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
NCT03318523
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
NCT03366337
MS PATHS Normative Sub-Study
NCT02996084
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
NCT03496012
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
NCT03507686
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
NCT03222973
A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
NCT03324685
Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults
NCT03264079
Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
NCT03224793
A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model
NCT03284931
Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074
NCT03385525
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
NCT03399981
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
NCT03068468
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
NCT02881567
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
NCT03068130
A Study to Evaluate SAGE-217 in Participants With Essential Tremor
NCT02978781
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
NCT03093324
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
NCT03116113
Long-Term Evaluation of BIIB067 (Tofersen)
NCT03070119
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
NCT03019185
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
NCT03056729
Scan-Rescan Sub-Study of MS PATHS
NCT04123353
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
NCT02978326
A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults
NCT02666963
A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
NCT03000530
New Formulation and Food Effect Study of BIIB074
NCT02951221
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
NCT03000569
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
NCT02847598
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
NCT02657356
A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
NCT02917187
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT02855411
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
NCT02829541
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
NCT02730455
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
NCT02833142
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
NCT02782975
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT02776072
Absorption, Metabolism, and Excretion Study of BIIB074
NCT02751905
Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers
NCT02691702
MSPT Device Usability Study
NCT02664324
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT02555215
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
NCT02658916
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
NCT02623699
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
NCT02611674
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
NCT02634307
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
NCT02594124
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
NCT02460094
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
NCT02410200
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
NCT02484547
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 135 |
| Phase 2 | 63 |
| Phase 3 | 71 |
| Phase 4 | 13 |
What is open in the Biogen pipeline
21 recruiting of 334 indexed (6% open); 237 completed (71%).
Phase mix: 84 late (III/IV) vs 198 early (I/II) (early-phase heavy).
Top condition: Multiple Sclerosis (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biogen: open-pipeline peers nationwide
Peers matched on 334 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Biogen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 334 trials (± recruiting share)
- National Institute on Drug Abuse (NIDA) · 335 trials · 4% recruiting
- Genentech · 332 trials · 7% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Altimmune · 6% recruiting · 16 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- Dynavax Technologies Corporation · 6% recruiting · 16 trials
Related
What to do with this Biogen page
334 registered trials is a research-attention snapshot, not an endorsement of Biogen or any single study.
- 21 of Biogen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition Biogen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biogen pipeline card: 334 registered trials from official public datasets.Report a data error.